Former USC player Armond Armstead settles lawsuit with USC

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Armond Armstead
    Armond Armstead
    LiveTodayTomorrowvs--|

Armond Armstead and USC have settled his lawsuit against the school, a team doctor and a medical center.

The former Trojan defensive end was suing because he said he suffered a heart attack in 2011 due to the overuse of Toradol. The painkiller was prescribed by USC's team doctor, James Tibone, who said in a court deposition that he didn't agree with the FDA cardiovascular warnings regarding the drug.

Terms of the settlement were not released. Armstead missed the 2011 season and was an undrafted free agent after he wasn't selected in the 2012 NFL draft.

“He believes that these athletes in particular are too often in a vulnerable position, without the resources or information necessary to make informed decisions regarding the use of Toradol, especially in game day circumstances where the drug might be used to get a player on the field in spite of an injury, when more conservative medical care might be more appropriate for the long term health of the student athlete,” Roger Dreyer, Armstead's lawyer, said in a statement via InsideSoCal.com.

Per Tibone's deposition, he also said he used his own judgment when it came to Toradol injections. After he was diagnosed with costochondritis in February 2011, Armstead was then diagnosed in March with a heart attack, a possible side effect of Toradol use. Armstead also said in court documents he had a second heart attack in 2014 while with the Patriots. He retired from football in July.

For more USC news, visit TrojanSports.com.

- - - - - - -

Nick Bromberg is the assistant editor of Dr. Saturday on Yahoo Sports. Have a tip? Email him at nickbromberg@yahoo.com or follow him on Twitter!

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting